<p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）在周四发布的研究报告中，Wells Fargo &amp; Company 的股票分析师将其目标价格从 30.00 美元上调至 35.00 美元，Benzinga 报道。该券商目前对该股票给予 “增持” 评级。Wells Fargo &amp; Company 的目标价格意味着该股票当前价格有 31.89% 的潜在上涨空间。</p>
<ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
<p>其他几位股票分析师也对 CNTA 发表了评论。Lifesci Capital 在 9 月 3 日的研究报告中将 Centessa Pharmaceuticals 的股票评级上调至 “强力买入”。Truist Financial 在 11 月 5 日的研究报告中对 Centessa Pharmaceuticals 的股票设定了 30.00 美元的目标价格。Guggenheim 在 10 月 6 日的报告中重申了 “买入” 评级，并设定了 28.00 美元的目标价格。Stephens 在 10 月 28 日的研究报告中开始覆盖 Centessa Pharmaceuticals，给予 “增持” 评级，并设定了 35.00 美元的目标价格。最后，Oppenheimer 在 8 月 29 日的研究报告中开始覆盖 Centessa Pharmaceuticals，给予 “跑赢大盘” 评级，并设定了 40.00 美元的目标价格。一位股票研究分析师给予该股票 “强力买入” 评级，十位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 33.11 美元。</p>
<p><strong>获取我们对 Centessa Pharmaceuticals 的最新股票分析</strong></p>
<h2>Centessa Pharmaceuticals 股票下跌 0.6%</h2>
<p>CNTA 的股票在周四的午盘交易中下跌 0.16 美元，报 26.54 美元。该公司的交易量为 829,726 股，而其平均交易量为 1,090,736 股。该股票的市值为 35.5 亿美元，市盈率为-14.56，贝塔值为 1.56。该公司的 50 日移动平均价格为 22.73 美元，200 日移动平均价格为 17.35 美元。该公司的速动比率为 10.57，流动比率为 10.56，债务与股本比率为 0.36。Centessa Pharmaceuticals 的 52 周最低价为 9.60 美元，52 周最高价为 27.18 美元。</p>
<p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益为-0.41 美元，低于分析师共识预期的-0.39 美元，差距为 0.02 美元。平均而言，股票研究分析师预测 Centessa Pharmaceuticals 在当前年度的每股收益为-1.6 美元。</p>
<h2>Centessa Pharmaceuticals 的内部买卖</h2>
<p>在其他新闻中，内部人士 Mario Alberto Accardi 在 9 月 16 日的交易中出售了 8,172 股公司的股票。该股票以平均价格 21.40 美元出售，总交易额为 174,880.80 美元。出售后，该内部人士直接持有 197,394 股公司的股票，价值为 4,224,231.60 美元。此次交易使其持股减少了 3.98%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席技术官 Tia L. Bush 在 9 月 24 日的交易中出售了 35,000 股股票。该股票以平均价格 24.00 美元出售，总价值为 840,000.00 美元。交易完成后，首席技术官持有 121,503 股公司的股票，价值为 2,916,072 美元。此次交易使其持股减少了 22.36%。该出售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了 145,964 股公司股票，价值为 3,169,861 美元。公司内部人士持有公司股票的 7.09%。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。纽约梅隆银行在第一季度收购了 Centessa Pharmaceuticals 的新股份，价值约为 147,000 美元。Cerity Partners LLC 在第一季度购买了 Centessa Pharmaceuticals 的新股份，价值 471,000 美元。Wildcat Capital Management LLC 在第一季度购买了 Centessa Pharmaceuticals 的新股份，价值 4,053,000 美元。Windmill Hill Asset Management Ltd 在第一季度收购了 Centessa Pharmaceuticals 的新股份，价值 1,696,000 美元。最后，XTX Topco Ltd 在第一季度将其在 Centessa Pharmaceuticals 的持股增加了 81.0%。XTX Topco Ltd 现在拥有 41,057 股公司的股票，价值 590,000 美元，此前在上个季度又购买了 18,377 股。目前 82.01% 的股票由机构投资者和对冲基金持有。</p>
<h2>Centessa Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于为患者发现、开发和提供药物。其产品管线包括 SerpinPC，一种用于治疗 A 型和 B 型血友病的活化蛋白 C 抑制剂；以及 ORX750，一种用于治疗嗜睡症和其他睡眠障碍的口服 OX2R 激动剂。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Centessa Pharmaceuticals</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>AMD 到 300 美元看起来很容易——这是为什么 500 美元可能是下一个</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>超过 50 亿美元的回购：DraftKings、AppLovin 和 Altria 在告诉你什么</li>
<li>精通纪律：克服交易中的情绪挑战</li>
<li>4 只高收益房地产股票，适合投资者防御性购买</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
<p>在你考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Centessa Pharmaceuticals 并不在名单上。</p>
<p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CNTA

<p>富国银行（Wells Fargo & Company）将 Centessa Pharmaceuticals（纳斯达克代码：CNTA）的目标股价从 30.00 美元上调至 35.00 美元，给予该股票 “超配” 评级。这表明相较于当前价格，潜在上涨幅度为 31.89%。其他分析师对 CNTA 也持积极评级，普遍评级为 “适度买入”，平均目标价格为 33.11 美元。Centessa Pharmaceuticals 的股票目前交易价格为 26.54 美元，市值为 35.5 亿美元</p>

<p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) had its target price boosted by stock analysts at Wells Fargo &amp; Company from $30.00 to $35.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. Wells Fargo &amp; Company's price target would indicate a potential upside of 31.89% from the stock's current price.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）在周四发布的研究报告中，Wells Fargo &amp; Company 的股票分析师将其目标价格从 30.00 美元上调至 35.00 美元，Benzinga 报道。该券商目前对该股票给予 “增持” 评级。Wells Fargo &amp; Company 的目标价格意味着该股票当前价格有 31.89% 的潜在上涨空间。</p>
</div><ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
</div><p>Several other equities analysts have also commented on CNTA. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Wednesday, September 3rd. Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Guggenheim reaffirmed a &#34;buy&#34; rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Stephens assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an &#34;overweight&#34; rating and a $35.00 price objective for the company. Finally, Oppenheimer started coverage on Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an &#34;outperform&#34; rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $33.11.</p>
<div class="lb-trans"><p>其他几位股票分析师也对 CNTA 发表了评论。Lifesci Capital 在 9 月 3 日的研究报告中将 Centessa Pharmaceuticals 的股票评级上调至 “强力买入”。Truist Financial 在 11 月 5 日的研究报告中对 Centessa Pharmaceuticals 的股票设定了 30.00 美元的目标价格。Guggenheim 在 10 月 6 日的报告中重申了 “买入” 评级，并设定了 28.00 美元的目标价格。Stephens 在 10 月 28 日的研究报告中开始覆盖 Centessa Pharmaceuticals，给予 “增持” 评级，并设定了 35.00 美元的目标价格。最后，Oppenheimer 在 8 月 29 日的研究报告中开始覆盖 Centessa Pharmaceuticals，给予 “跑赢大盘” 评级，并设定了 40.00 美元的目标价格。一位股票研究分析师给予该股票 “强力买入” 评级，十位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 33.11 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Centessa Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Centessa Pharmaceuticals Stock Down 0.6%</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股票下跌 0.6%</h2>
</div><p>Shares of CNTA traded down $0.16 during midday trading on Thursday, hitting $26.54. The company had a trading volume of 829,726 shares, compared to its average volume of 1,090,736. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -14.56 and a beta of 1.56. The company's 50 day moving average price is $22.73 and its 200 day moving average price is $17.35. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $27.18.</p>
<div class="lb-trans"><p>CNTA 的股票在周四的午盘交易中下跌 0.16 美元，报 26.54 美元。该公司的交易量为 829,726 股，而其平均交易量为 1,090,736 股。该股票的市值为 35.5 亿美元，市盈率为-14.56，贝塔值为 1.56。该公司的 50 日移动平均价格为 22.73 美元，200 日移动平均价格为 17.35 美元。该公司的速动比率为 10.57，流动比率为 10.56，债务与股本比率为 0.36。Centessa Pharmaceuticals 的 52 周最低价为 9.60 美元，52 周最高价为 27.18 美元。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). On average, equities research analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益为-0.41 美元，低于分析师共识预期的-0.39 美元，差距为 0.02 美元。平均而言，股票研究分析师预测 Centessa Pharmaceuticals 在当前年度的每股收益为-1.6 美元。</p>
</div><h2>Insider Buying and Selling at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的内部买卖</h2>
</div><p>In other news, insider Mario Alberto Accardi sold 8,172 shares of the business's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total transaction of $174,880.80. Following the sale, the insider directly owned 197,394 shares of the company's stock, valued at $4,224,231.60. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 35,000 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total value of $840,000.00. Following the completion of the transaction, the chief technology officer owned 121,503 shares of the company's stock, valued at $2,916,072. This trade represents a 22.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 145,964 shares of company stock valued at $3,169,861. Corporate insiders own 7.09% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Mario Alberto Accardi 在 9 月 16 日的交易中出售了 8,172 股公司的股票。该股票以平均价格 21.40 美元出售，总交易额为 174,880.80 美元。出售后，该内部人士直接持有 197,394 股公司的股票，价值为 4,224,231.60 美元。此次交易使其持股减少了 3.98%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席技术官 Tia L. Bush 在 9 月 24 日的交易中出售了 35,000 股股票。该股票以平均价格 24.00 美元出售，总价值为 840,000.00 美元。交易完成后，首席技术官持有 121,503 股公司的股票，价值为 2,916,072 美元。此次交易使其持股减少了 22.36%。该出售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了 145,964 股公司股票，价值为 3,169,861 美元。公司内部人士持有公司股票的 7.09%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter valued at approximately $147,000. Cerity Partners LLC purchased a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at $471,000. Wildcat Capital Management LLC purchased a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at $4,053,000. Windmill Hill Asset Management Ltd acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter worth $1,696,000. Finally, XTX Topco Ltd grew its holdings in shares of Centessa Pharmaceuticals by 81.0% during the first quarter. XTX Topco Ltd now owns 41,057 shares of the company's stock valued at $590,000 after buying an additional 18,377 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。纽约梅隆银行在第一季度收购了 Centessa Pharmaceuticals 的新股份，价值约为 147,000 美元。Cerity Partners LLC 在第一季度购买了 Centessa Pharmaceuticals 的新股份，价值 471,000 美元。Wildcat Capital Management LLC 在第一季度购买了 Centessa Pharmaceuticals 的新股份，价值 4,053,000 美元。Windmill Hill Asset Management Ltd 在第一季度收购了 Centessa Pharmaceuticals 的新股份，价值 1,696,000 美元。最后，XTX Topco Ltd 在第一季度将其在 Centessa Pharmaceuticals 的持股增加了 81.0%。XTX Topco Ltd 现在拥有 41,057 股公司的股票，价值 590,000 美元，此前在上个季度又购买了 18,377 股。目前 82.01% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于为患者发现、开发和提供药物。其产品管线包括 SerpinPC，一种用于治疗 A 型和 B 型血友病的活化蛋白 C 抑制剂；以及 ORX750，一种用于治疗嗜睡症和其他睡眠障碍的口服 OX2R 激动剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Centessa Pharmaceuticals</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>AMD 到 300 美元看起来很容易——这是为什么 500 美元可能是下一个</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>超过 50 亿美元的回购：DraftKings、AppLovin 和 Altria 在告诉你什么</li>
<li>精通纪律：克服交易中的情绪挑战</li>
<li>4 只高收益房地产股票，适合投资者防御性购买</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Centessa Pharmaceuticals 并不在名单上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

富国银行的分析师表示，Centessa Pharmaceuticals（纳斯达克股票代码：CNTA）的股价预计将会上涨